Coherus Oncology, Inc. (CHRS)
1.135
0.00 (0.00%)
USD |
NASDAQ |
Sep 28, 16:00
1.135
0.00 (0.00%)
After-Hours: 16:40
Coherus Oncology Research and Development Expense (TTM) : 97.61M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 97.61M |
| March 31, 2026 | 102.32M |
| December 31, 2025 | 104.96M |
| September 30, 2025 | 94.61M |
| June 30, 2025 | 88.83M |
| March 31, 2025 | 82.95M |
| December 31, 2024 | 86.56M |
| September 30, 2024 | 92.14M |
| June 30, 2024 | 95.64M |
| March 31, 2024 | 98.62M |
| December 31, 2023 | 101.31M |
| September 30, 2023 | 103.97M |
| June 30, 2023 | 125.77M |
| March 31, 2023 | 145.00M |
| December 31, 2022 | 198.31M |
| September 30, 2022 | 220.26M |
| June 30, 2022 | 227.64M |
| March 31, 2022 | 239.89M |
| December 31, 2021 | 359.62M |
| September 30, 2021 | 353.48M |
| June 30, 2021 | 338.45M |
| March 31, 2021 | 310.06M |
| December 31, 2020 | 139.91M |
| September 30, 2020 | 130.02M |
| June 30, 2020 | 112.63M |
| Date | Value |
|---|---|
| March 31, 2020 | 106.04M |
| December 31, 2019 | 92.33M |
| September 30, 2019 | 85.10M |
| June 30, 2019 | 92.04M |
| March 31, 2019 | 99.67M |
| December 31, 2018 | 106.34M |
| September 30, 2018 | 111.11M |
| June 30, 2018 | 126.03M |
| March 31, 2018 | 134.01M |
| December 31, 2017 | 162.33M |
| September 30, 2017 | 189.91M |
| June 30, 2017 | 211.86M |
| March 31, 2017 | 242.90M |
| December 31, 2016 | 254.44M |
| September 30, 2016 | 246.86M |
| June 30, 2016 | 250.51M |
| March 31, 2016 | 241.91M |
| December 31, 2015 | 213.06M |
| September 30, 2015 | 188.50M |
| June 30, 2015 | 138.77M |
| March 31, 2015 | 100.76M |
| December 31, 2014 | 78.22M |
| September 30, 2014 | 60.58M |
| June 30, 2014 | 47.02M |
| March 31, 2014 | 36.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Enanta Pharmaceuticals, Inc. | 86.24M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |